October 2021 Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial
October 2021 OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study
October 2021 OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT
October 2021 OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting
October 2021 OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo®
October 2021 OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of CoVepiT
October 2021 OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with BI 765063